Combining recombinant protein and fibrin spray to increase wound healing

Overview

A little-appreciated complication of pneumonia in surgical patients is decreased wound healing. We have invented a treatment method that uses fibrin spray as a vehicle to topically deliver one or more chemokines to accelerate wound healing. Advantages of our method include effectiveness, ease of application, and the use of already-approved clinical products.

Market Opportunity

Most studies of immune system function focus on single insults, such as infection or injury. Though post-surgical pneumonia is a well-known clinical complication, very little is known about the interactions between pulmonary infection and inflammation in other tissues, e.g., dermal tissue, or of the immune system’s response to those interactions. Given the role of concurrent infection in decreased wound healing, there is a clinical need for ways to support cutaneous wound healing in those who have, or are at risk of, a pulmonary infection or injury.

Innovation and Meaningful Advantages

Our research suggests that, directed by competing chemokine signals, the immune system prioritizes, or triages, inflammatory sites. This finding suggests the potential for chemokine-directed therapies to counteract the negative effects of immune-system triage in patients fighting multiple inflammatory insults. We have discovered a decrease in several chemokines (a type of cytokine, or signaling molecule) important to attracting innate immune cells essential to wound healing. We have invented a treatment method that uses fibrin spray as a vehicle to topically deliver one or more chemokines to accelerate wound healing. Advantages of our method include effectiveness, ease of application, and the use of already-approved clinical products.

Collaboration Opportunity

We are interested in exploring 1) research collaborations with leading pharmaceutical companies to develop this treatment; and 2) licensing opportunities for drug delivery companies.

Principal Investigator

Amanda Jamieson, PhD

Esther Elizabeth Brintzenhoff Associate Professor of Molecular Microbiology

Brown University

amanda_jamieson@brown.edu 

https://vivo.brown.edu/display/ajamieso#Background

IP Information

US Utility US-2020-0353046-A1, Published November 12, 2020

Publications

Crane MJ, Xu Y, Monaghan SF, Hall BM, Albina JE, Henry Jr. WL, Tran HL, Chhabria KRP, Jordon ARD, Carlsen L, Jamieson AM. Pulmonary infection interrupts acute cutaneous wound healing through disruption of chemokine signals. bioRxiv 2020 May 10. doi.org/10.1101/2020.05.08.084442.

 

Contact

Andrew Bond, PhD

Senior Director of Business Development

andrew_bond@brown.edu

Brown Tech ID 3164

 

Patent Information:
Category(s):
Therapeutics
For Information, Contact:
Brown Technology Innovations
350 Eddy Street - Box 1949
Providence, RI 02903
tech-innovations@brown.edu
401-863-7499
Inventors:
Amanda Jamieson
Meredith Crane
Yun Xu
Keywords:
© 2024. All Rights Reserved. Powered by Inteum